Hundreds of laid-off CDC employees are being reinstated
NEW YORK (AP) — More than 460 laid-off employees at the nation's top public health agency received notices Wednesday that they are being reinstated, according to a union representing the workers.
The U.S. Department of Health and Human Services confirmed reinstatement notices went out to the former Centers for Disease Control and Prevention employees, but provided few details.
About 2,400 CDC employees lost their jobs in a wave of cuts across federal health agencies in early April, according to a tally at the time.
Whole CDC programs were essentially shut down, including some focused on smoking, lead poisoning, gun violence, asthma and air quality, and workplace safety and health. The entire office that handles Freedom of Information Act requests was shuttered. Infectious disease programs took a hit, too, including programs that fight outbreaks in other countries, labs focused on HIV and hepatitis in the U.S., and staff trying to eliminate tuberculosis.
An estimated 200 of the reinstated workers are based in the CDC's National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention, HHS officials confirmed. Staffers at a CDC lab that does testing for sexually transmitted diseases are being brought back, said one CDC employee who wasn't authorized to discuss what happened and spoke to The Associated Press on condition of anonymity.
Also reinstated are an estimated 150 employees at the CDC's National Center for Environmental Health, including people staffing a lab that works on lead poisoning, according to the union and employees.
Layoffs at federal agencies were challenged in lawsuits, with judges in some cases ordering federal agencies to halt terminations of employees.
Officials at HHS have never detailed how they made the layoff decisions in the first place. And they did not answer questions about why the notices went out, or how decisions were made about who to bring back.
HHS spokesperson Andrew Nixon said the agency was streamlining operations and that 'the nation's critical public health functions remain intact and effective.'
'The Trump Administration is committed to protecting essential services — whether it's supporting coal miners and firefighters through NIOSH, safeguarding public health through lead prevention, or researching and tracking the most prevalent communicable diseases,' he said.
This is not the first time that employees at the Atlanta-based agency were told they were being terminated only to then be told to come back. After an earlier round of termination notices went out in February, about 180 CDC employees in March were told to come back.
__
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
28 minutes ago
- Associated Press
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesity, once-weekly subcutaneous amycretin appeared to be safe and tolerable in trial participants, who also achieved significantly greater weight loss across the full range of doses investigated versus placebo.1 A related phase 1 trial of once-daily oral amycretin in adults with obesity or overweight also showed that treatment was safe and tolerable with an observed reduction in body weight compared to placebo.2 No weight loss plateau was observed in either trial at the end of the respective treatment durations.1,2 Data on subcutaneous amycretin is scheduled to be presented on Sunday, June 22nd, during a late-breaking poster session at the American Diabetes Association's® (ADA) 85th Scientific Sessions.1 'We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management. At Novo Nordisk, we understand that addressing obesity is a complex challenge that many patients face. These results reflect our robust pipeline in obesity, our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'We remain steadfast in our mission to discover and develop therapies that can have a meaningful impact in the lives of those affected by obesity.' Results from the phase 1b/2a trial of subcutaneous amycretin showed treatment-emergent adverse events (TEAEs) were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most frequent reported TEAEs were gastrointestinal in nature. Compared to placebo, participants receiving amycretin observed greater weight loss across the full range of doses investigated.1 Subcutaneous amycretin at multiple doses demonstrated greater weight reduction than placebo at the end of the trial. Participants who received the highest doses (up to 60 mg) reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment. Results from this first-in-human phase 1b/2a study support further investigation of potential weight-loss efficacy of amycretin. Results from the published phase 1 trial of oral amycretin showed that the most common TEAEs were related to gastrointestinal symptoms (mainly nausea and vomiting) and decreased appetite; these were most frequent for the higher doses. Trial participants receiving the study treatment demonstrated significantly greater weight loss across the full range of doses investigated versus the placebo group.2 Exploratory results showed participants taking 100 mg per day of oral amycretin achieved a mean weight loss of 13.1% versus 1.2% with placebo after 12 weeks.2 Based on these phase 1 results, longer evaluation with more participants is warranted to substantiate the full efficacy findings of oral amycretin on body weight reductions and changes in metabolic parameters. Novo Nordisk will advance both subcutaneous and oral amycretin formulations straight to phase 3 development for weight management based on these and other completed clinical studies, as well as feedback received from regulatory authorities. About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration, and is not approved in the US for weight loss. About the phase 1b/2a subcutaneous amycretin trial The phase 1b/2a trial was a randomized, placebo-controlled, single-center, double-blinded study of 125 participants assessing the safety, tolerability, pharmacokinetics, and effects on body weight after subcutaneous administration of amycretin in people with overweight or obesity.1 Adults with a body mass index of 27-39.9kg/m2 and glycated hemoglobin (HbA1c) <6.5% were eligible for the trial.1 The trial was conducted in 5 parts: a single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B).1 Lastly, in the multiple ascending dose – dose response parts, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).1 About the phase 1 oral amycretin trial The phase 1 single-center, randomized, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (Part A) and multiple ascending doses (Part B, 10 days of treatment; Part C/D, 12 weeks of treatment) of 144 adult participants with overweight or obesity.2 The primary endpoint was the number of treatment-emergent adverse events (TEAEs) observed in the trial. The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.2 About obesity Obesity is a serious chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.8,9 In the US, about 40% of adults live with obesity.10 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information References © 2025 Novo Nordisk All rights reserved. US25SEMO01477 June 2025 View original content to download multimedia: SOURCE NOVO NORDISK INC.
Associated Press
28 minutes ago
- Associated Press
Banyan & Bamboo Launches AI-Powered '365 Beauty Blueprint' for Personalized Aesthetic Wellness in Austin
Austin's most soulful med spa is now one of its smartest. Banyan & Bamboo Day Spa + Med Spa unveils the '365 Beauty Blueprint' - a regenerative aesthetic protocol blending advanced facial mapping with deeply personalized, year-round wellness planning. Austin, TX, Texas, United States, June 21, 2025 -- Women-Led Spa Debuts Year-Round Aesthetic Strategy Backed by AI Banyan & Bamboo Day Spa + Med Spa, a boutique, women-led studio in the heart of Austin, today announces the launch of its signature 365 Beauty Blueprint, a highly personalized treatment plan guided by advanced AI skin mapping. This milestone reflects the spa's commitment to natural, data-backed results in regenerative aesthetics, setting a new standard for long-term self-care. In a field often driven by fleeting trends and one-size-fits-all treatments, Banyan & Bamboo introduces a new kind of beauty planning - one rooted in personalization, cellular science, and soulful care. Banyan & Bamboo's AI skin analysis and 365-day treatment plan is one of the most personalized options for injectables and facial care in Austin. 'We don't believe in one-size-fits-all beauty,' says Jennifer Rushing, Owner and Founder. 'We co-create yearlong blueprints that support skin, confidence, and health from the inside out.' Precision Meets Personalization: The 365 Beauty Blueprint At the heart of the new offering is AI-powered skin analysis - a diagnostic tool that maps hydration, pigmentation, texture, sun damage and aging markers. These insights allow the team to design evolving treatment plans that respond to each client's changing skin needs. The 365 Beauty Blueprint integrates: Every service within the protocol is selected to support internal wellness and natural-looking refinement. Regenerative Aesthetics in a Spa-Like Setting Blending clinical innovation with spa-caliber care, Banyan & Bamboo offers a slower, deeper, and more restorative alternative to volume-focused chains. Each visit includes in-depth consultation, customized protocols, and education - empowering clients to feel confident, cared for, and in control of their treatment journey. 'Our clients aren't here for a quick fix,' says Lindsey R., Spa Manager and Guest Experience Coordinator. 'They come to us because we spend time, educate them, and offer treatments that support long-term beauty and wellness.' Shifting the Industry Toward Longevity and Intention Since opening its doors, Banyan & Bamboo has cultivated one of the most loyal client communities in Central Texas. With the 365 Beauty Blueprint, the studio deepens its philosophy: beauty is not a single service, it's a long-term relationship. From hormone-safe skincare to regenerative injectables, each blueprint is crafted with intention and backed by science. The result is an customized aesthetic plan that's as restorative as it is effective - one that meets modern clients where they are and grows with them. 'Austin deserves more than cookie-cutter med spas,' adds Rushing. 'Our goal is to bring intention, expertise, and a little bit of Austin soul into every appointment.' Award-Winning Service In addition to the launch of the 365 Beauty Blueprint, Banyan & Bamboo is also celebrating a recent recognition as the Best Day Spa + Med Spa in Austin of 2025 by the prestigious Evergreen Awards. This accolade highlights their exceptional contributions to the wellness and aesthetics industry, particularly their blend of clinical precision and personalized care. Known for offering a standout menu of evidence-based aesthetic and wellness services, the spa's commitment to the natural, sustainable approach to beauty is reflected in their award. Banyan & Bamboo's regenerative aesthetics, including neuromodulators, dermal fillers, biostimulants, and cutting-edge injectable wellness therapies, consistently deliver natural results, backed by advanced AI-powered skin analysis for hyper-customized facial treatment plans. This focus on personalized, regenerative aesthetics, combined with their holistic approach, has fostered loyalty and built lasting relationships with clients. Owner and Founder Jennifer Rushing's leadership and the spa's deep connection with their clients have played a pivotal role in the studio's success, creating an environment where beauty meets wellness in a thoughtful, intentional way. About Banyan & Bamboo Day Spa | Med Spa Banyan & Bamboo is a boutique day spa and med spa in Austin, TX, specializing in regenerative aesthetics and clinical wellness treatments. The women-led studio offers AI-driven skin analysis, facial balancing, PRF therapies, injectable wellness services, and customized treatment blueprints. Built on the belief that science and soul should coexist, the spa delivers natural-looking results that last - inside and out. Media Contact: Name: Jennifer Rushing Title: Owner & Founder Email: [email protected] Contact Info: Name: Jennifer Rushing Email: Send Email Organization: Banyan & Bamboo Website: Release ID: 89162872 Should any errors, concerns, or inconsistencies arise from the content provided in this press release that require attention or if a press release needs to be taken down, we kindly request that you immediately contact us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for timely assistance within 8 hours – taking necessary measures to rectify identified issues or providing guidance on the removal process. We prioritize delivering accurate and reliable information.
Yahoo
2 hours ago
- Yahoo
24-Acre Minnetonka Complex Put Up for Sale by Boston Scientific (BSX)
Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to buy. On June 10, the company announced that it is selling one suburban Twin Cities property and expanding another, mirroring a pattern of companies centralizing in fewer but more dynamic sites. BSX has placed its 226,000 square foot Minnetonka campus on the market, indicating the wind-down of its presence in that suburb. Meanwhile, it is enlarging its Maple Grove operations with a new 52,000 square foot buildout at its 79-acre Weaver Lake location. That $139.4 million development seems relatively small beside Boston Scientific's second Maple Grove site, which is a $170 million, 400,000 square foot facility where staff are expected to begin moving in before year's end. A surgeon examining a patient's brain in an operating room, paramedics nearby. CBRE's listing describes the Minnetonka property as containing labs, warehousing, and top-tier offices. Though no asking price is listed, county records place the combined 2025 value of four adjacent parcels at $14.8 million. Boston Scientific employed around 10,000 people in Minnesota as of March, including sites in Minnetonka, Maple Grove, and a sizable Arden Hills facility. The number of employees has roughly doubled over 15 years. Despite its Massachusetts roots, the company runs all eight of its divisions in Minnesota, including its flagship cardiology arm. The company did not respond to specific queries about the Minnetonka sale, including the functions housed there or implications for workforce downsizing. The real estate listing indicates the company may lease the site until mid-2026 but plans a complete exit thereafter. Boston Scientific Corporation (NYSE:BSX), a global player in medical device innovation, operates through its Cardiovascular and MedSurg segments to deliver advanced diagnostic and therapeutic technologies. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
